The long and winding road towards new treatments against lymphatic filariasis and onchocerciasis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Abstract:
      Ivermectin (IVM), diethylcarbamazine (DEC) plus albendazole (ALB) – IDA – should be incorporated on a larger scale and adopted for mass drug administration (MDA) campaigns for filarial infections. Novel macrofilaricidal treatments are urgently needed to eliminate filarial infections. The developmental pipeline for new treatments continues to be limited. Cooperation between academia, pharmaceutical companies, non-governmental organizations (NGOs), and local stakeholders is essential to facilitate the development, production, and distribution of new treatment strategies. Although lymphatic filariasis and onchocerciasis have been targeted for global elimination, these helminth infections are still a major public health problem across the tropics and subtropics. Despite decades of research, treatment options remain limited and drugs that completely clear the infections, and can be used on a large scale, are still unavailable. In the present review we discuss the strengths and weaknesses of currently available treatments and new ones in development. Novel candidates (corallopyronin A, DNDi-6166, emodepside, and oxfendazole) are currently moving through (pre)clinical development, while the development of two candidates (AWZ1066S and ABBV-4083/flubentylosin) was recently halted. The preclinical R&D pipeline for filarial infections continues to be limited, and recent setbacks highlight the importance of continuous drug discovery and testing. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Trends in Parasitology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)